PATCH: platelet transfusion in cerebral haemorrhage: study protocol for a multicentre, randomised, controlled trial by Gans, K. de et al.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/169606
 
 
 
Please be advised that this information was generated on 2017-12-07 and may be subject to
change.
STUDY PROTOCOL Open Access
Patch: platelet transfusion in cerebral
haemorrhage: study protocol for a multicentre,
randomised, controlled trial
Koen de Gans1*, Rob J de Haan2, Charles B Majoie3, Maria M Koopman4, Anneke Brand5,6, Marcel G Dijkgraaf7,
Marinus Vermeulen1, Yvo B Roos1,2, the PATCH Investigators
Abstract
Background: Patients suffering from intracerebral haemorrhage have a poor prognosis, especially if they are using
antiplatelet therapy. Currently, no effective acute treatment option for intracerebral haemorrhage exists. Limiting
the early growth of intracerebral haemorrhage volume which continues the first hours after admission seems a
promising strategy. Because intracerebral haemorrhage patients who are on antiplatelet therapy have been shown
to be particularly at risk of early haematoma growth, platelet transfusion may have a beneficial effect.
Methods/Design: The primary objective is to investigate whether platelet transfusion improves outcome in
intracerebral haemorrhage patients who are on antiplatelet treatment. The PATCH study is a prospective,
randomised, multi-centre study with open treatment and blind endpoint evaluation. Patients will be randomised to
receive platelet transfusion within six hours or standard care. The primary endpoint is functional health after three
months. The main secondary endpoints are safety of platelet transfusion and the occurrence of haematoma
growth. To detect an absolute poor outcome reduction of 20%, a total of 190 patients will be included.
Discussion: To our knowledge this is the first randomised controlled trial of platelet transfusion for an acute
haemorrhagic disease.
Trial registration: The Netherlands National Trial Register (NTR1303)
Background
In studies on outcome prediction after intracerebral hae-
morrhage (ICH), increasing haematoma volume is a
consistent, independent predictor of poor outcome [1,2].
A study with follow-up head CT-scans in the acute
phase showed a ≥ 33% increase of haematoma volume
during the first 24 hours in at least 38% of patients [3].
This haematoma growth mostly occurs in the first six
hours after onset [4,5]. Unsurprisingly, patients suffering
from haematoma growth have worse outcome than
those without haematoma growth [6]. At our institution
we investigated the in hospital mortality after sponta-
neous ICH. We retrospectively reviewed the charts of all
ICH patients who were admitted over a three year per-
iod and divided them in three groups. Patients using
antiplatelet therapy (APT) had a 40% in hospital mortal-
ity (15/38 patients). In patients using oral anticoagulants
the mortality rate was 28% during stay in the hospital
(11/39) and patients without any antithrombotic medi-
cation had a 23% mortality (27/118). This poor outcome
for APT patients was unexpected. We first considered
this high mortality rate to be an epiphenomenon since
the APT patients were older and had more previous car-
diovascular events. However, other groups had reported
similar results and identified APT use as an independent
risk factor for poor outcome [7-12].
A possible explanation for poor outcome in patients
on APT is haematoma growth. A population-based
study in 208 ICH patients showed that the baseline hae-
matoma volume was comparable between patients who
used APT and those who did not [11]. In contrast,
patients using oral anticoagulants had a significantly lar-
ger haematoma on admission. Although APT use had
* Correspondence: k.degans@amc.uva.nl
1Department of Neurology, Academic Medical Centre, H2-222, PO-box 22660
1100 DD Amsterdam, The Netherlands
de Gans et al. BMC Neurology 2010, 10:19
http://www.biomedcentral.com/1471-2377/10/19
© 2010 de Gans et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
no influence on haematoma volume on admission, there
was more haematoma growth in patients on APT as
compared to patients not using any antithrombotic
medication. Another study also found that haematoma
growth occurs more often in patients using APT [9].
We concluded that antiplatelet agents do not cause a
more severe initial haemorrhage, but the hampered
platelet function does more often lead to increasing
haemorrhage in the first few hours after haemorrhage
onset - i.e. haematoma growth.
It seems likely that a treatment strategy which stops
this increase of haematoma volume will improve out-
come in ICH patients. Such an intervention should be
initiated as rapidly as possible to maximise its benefit. It
is hypothesised that the best and fastest treatment
option to counteract the effect of APT is platelet trans-
fusion. Similar as in other acute life threatening haemor-
rhagic conditions, such as severe oesophageal bleeding
in patients who were using APT, platelet transfusion is
often a routine measure. However, a randomised con-
trolled trial to study the effectiveness of platelet transfu-
sion in acute life threatening haemorrhage has never
been performed since this treatment is considered to be
absolutely necessary or futile.
Methods/Design
Objective
The primary aim of the PATCH trial is to investigate
whether platelet transfusion reduces poor outcome at
3 months in ICH patients who were using antiplatelet
treatment. Poor outcome is defined as a modified Ran-
kin Scale (mRS) score of 4 to 6.
Study design
The PATCH study is a prospective randomised open
label trial with a blind endpoint evaluation (PROBE).
This PROBE design is used since placebo treatment for
platelet transfusion is not feasible. The development of a
placebo is impossible as platelets show a unique swirl in
the bag and the option of transfusion using opaque trans-
fusion bags and iv-lines was deemed highly unpractical.
A total of 38 academic, teaching and regional hospi-
tals in The Netherlands are currently participating
[appendix I]. Participation of additional centres from the
United Kingdom is expected. Other centres are encour-
aged to participate as well.
Ethical considerations
Full ethical approval for the study was obtained from
the Medical Ethics Committee from the Academic Med-
ical Centre, University of Amsterdam on March 10,
2008. All participating centres’ ethical committees
assessed the study and provided a declaration of
participation.
The PATCH trial will be conducted according to the
principles of the Declaration of Helsinki (version of
2004) and in accordance with the Medical Research
Involving Human Subjects Act (WMO). Data manage-
ment, monitoring and reporting of the study will be per-
formed in accordance with the ICH-GCP guidelines.
Patient population
Patients with ICH who were using antiplatelet agents
during the seven days preceding haemorrhage are eligi-
ble for the study. This includes patients with ICH on
acetylsalicic acid, carbasalate calcium, clopidogrel,
dipyridamole or a combination of these drugs. Patients
using oral anticoagulants such as warfarin are
excluded.
Inclusion criteria
1. Age ≥ 18 years
2. Non-traumatic, supratentorial ICH confirmed by
head CT-scan
3. Glasgow Coma Scale score 8-15
4. Antiplatelet agents used at least during the seven
days preceding haemorrhage
5. Treatment can be initiated within 6 hours after
onset of first signs and within 1 1/2 hours of the diag-
nostic CT-scan
6. Pre-stroke modified Rankin Scale score of 0 or 1
(No symptoms, No significant disability despite symp-
toms; able to carry out all usual duties and activities)
7. Written informed consent is obtained
Exclusion criteria
1. Haematoma on CT-scan suggestive of epidural,
subdural, aneurysmal or arterio-venous malformation
haematoma (judged by treating physicians)
2. Planned surgical evacuation of haematoma within
24 hours after admission
3. Presence of intraventricular blood more than sedi-
mentation in the posterior horns of the lateral ventricles
4. Previous adverse reaction to platelet transfusion
5. Known use of vitamin K antagonists (unless INR ≤ 1.3)
6. Known thrombocytopenia < 100 × 109/l
7. History of coagulopathy
8. Previously legally incompetent adults prior to stroke
9. Death appears imminent
Outcome
The primary endpoint is functional health at three
months scored on the modified Rankin Scale. Poor out-
come is defined as a score of 4-6: (moderately) severe
disability or death.
Secondary endpoints are: safety of platelet transfusion,
the occurrence of haematoma growth, predictive value
of the CTA “spot sign” regarding poor outcome and
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haematoma growth, survival at three months, disability
at three months scored using the AMC linear disability
score (ALDS), functional health using the full ordinal
scoring range of the mRS at three months, poor out-
come at three months defined as mRS 3-6, causes of
poor outcome and costs.
The primary outcome and a set of secondary out-
comes are assessed by a trained research nurse and a
radiologist blinded for treatment allocation.
Sample size
Based on large cohort studies we estimate that in our
patient population at least 70% will have poor outcome
(mRS 4-6). We aim to reduce this percentage of poor
outcome to 50%, a treatment effect which is considered
to be highly clinically relevant in ICH. A two group X2
test with a 0,05 two-sided significance level will have
80% power to detect the difference between the control
group proportion of 0,70 and an experimental group
proportion of 0,50 (odds ratio of 0,429) when the sam-
ple size in each group is 95 (total group 190 patients).
With this sample size, a two-sided 95% confidence inter-
val for the difference between the proportions will
extend 0,136 from the observed difference in
proportions.
Randomisation
Patients are randomised to receive either platelet trans-
fusion or standard care without platelet transfusion.
The randomisation procedure is computer- and web-
based, using permuted blocks and is stratified by study
centre and type of antiplatelet agent (acetylsalicic acid,
carbasalate calcium, clopidogrel, dipyridamole or a com-
bination). Randomisation software (ALEA) is made
available by the Clinical Research Unit of the Academic
Medical Centre.
Intervention
Platelet transfusion consists of a single gift of 5 or
10 donor units (one or two bags of a standard prophy-
lactic dose, which consists in the Netherlands of 5 pooled
buffy-coat derived platelets). The number of donor units
depends on the type of medication used. All patients
will receive a pooled platelet concentrate of 5 units
except for patients using clopidogrel as mono-therapy
or in combination with other APT who will receive two
pooled concentrates (10 donor units).
The treatment must be initiated as soon as possible
but at least within 6 hours after onset of symptoms.
This six hour time limit was agreed upon since haema-
toma growth mainly occurs in the first hours. One of
the secondary endpoints is haematoma growth in the
first 24 hours. The 1 1/2 hour time window between the
diagnostic CT-scan and start of treatment was chosen
because of this endpoint. More time between CT and
treatment could lead to a failure of treatment effect for
this endpoint.
Data collection
Data will be collected at five distinct moments: on
admission, after one hour, after 24 hours (+/- 3), at dis-
charge and after 3 months.
On admission patients characteristics (including age,
gender, length, weight, medical history, pre-stroke medi-
cation), physical examination (including Glasgow Coma
Scale score, stroke severity on the NIH stroke scale),
laboratory test results, time between onset of symptoms
and treatment start are recorded and the diagnostic CT
scan, and a CTA of the cerebral vessels are analysed.
One hour after transfusion platelet count is deter-
mined. In selected centres additional platelet function
testing is done. After 24 hours a follow-up non-contrast
head CT-scan is performed. A third platelet count and
platelet function testing is optional. At discharge the
date and destination are noted. Follow-up is performed
by a telephone interview three months after
randomisation.
On the initial and 24 hour CT-scans haematoma
volume is measured using computerised volumetric ana-
lysis. The spot sign and spot sign score will be scored
on the CTA source images. In one centre (St Antonius
Hospital Nieuwegein) haematoma volume will be moni-
tored with transcranial doppler (TCD).
Follow-up measurements
At three months the primary outcome (modified Rankin
score) is assessed by a research nurse from the clinical
trial bureau of the coordinating centre, who is blinded
for treatment, and who will score the functional health
outcome by telephone using a structured interview. To
increase the inter-observer reliability the number of
research nurses will be limited to a maximum of two.
An inter-observer variability assessment on primary out-
come was performed by the AMC Clinical Research
Unit before the PATCH study started. The other clinical
outcome measure, the Amsterdam Linear Disability
Score (ALDS) will be assessed by the same research
nurse during the same telephone interview [13].
The radiological outcomes are assessed by a radiolo-
gist blinded for treatment allocation.
Statistical analysis
Baseline characteristics will be summarized using simple
descriptive statistics. The main analysis of the PATCH
study consists of a single comparison between the trial
treatment groups of the primary outcome after three
months (dichotomized mRS score). The analysis will be
based on the intention-to-treat principle. The effect size
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will be expressed in a relative risk estimates and abso-
lute risk reduction. Additionally the primary outcome
will be analyzed using multivariate logistic regression,
adjusting (if necessary) for clinically relevant baseline
imbalances and treatment characteristics. The effect size
will be expressed in an adjusted odds ratio (OR). With
regard to the range of secondary outcome parameters
we will use simple 2 × 2 tables, two-group t-tests,
Mann-Whitney tests, and multivariate linear and logistic
regression models, when appropriate. With respect to
the primary outcome predefined subgroup-analyses will
be performed: a) different kinds of PAI used by the
patient, b) treatment within 2.5 hours versus 2.5 -
6 hours after symptom onset. In all analyses, statistical
uncertainty will be quantified via 95% confidence
intervals.
Safety
The study will be carried out in accordance with Dutch
legislation and International Conference on Harmonisa-
tion/Good Clinical Practice (ICH-GCP) standards.
Adverse events are defined as any undesirable experi-
ence occurring to a subject during a clinical trial,
whether or not considered related to the investigational
drug. All adverse events reported spontaneously by the
subject or observed by the investigator or his staff will
be recorded.
A serious adverse event (SAE) is any untoward medi-
cal occurrence or effect that at any dose:
▪ results in death;
▪ is life threatening (at the time of the event);
▪ requires hospitalisation or prolongation of existing
inpatients’ hospitalisation;
▪ results in persistent or significant disability or
incapacity;
If an SAE occurs, the principal investigators will be
notified by e-mail or telephone within 24 hours. All
SAEs will be reported to the central MEC, according to
their requirements.
The investigator will report all suspected unexpected
serious adverse reactions (SUSARs) that could have con-
sequences for the safety of the subjects involved in the
PATCH-Trial, expedited to the central MEC (Medical
Ethics Committee), DSMB (Data Safety Monitoring
Board) and competent national authorities, including
SUSARs that have arisen in other clinical trials with the
same treatment [appendix II].
The DSMB is an independent committee of trial
experts who will focus on both safety monitoring and
analysis of unblinded effectiveness data. The DSMB con-
sists of three members: 2 clinicians and 1 epidemiolo-
gist. The DSMB will perform ongoing safety
surveillances, especially with regard to the occurrence of
serious adverse events in terms of thrombotic
complications of venous or arterial origin and transfu-
sion reactions. The investigator will report the occur-
rences of these events to the chairman on a weekly
basis. The DSMB can recommend the Steering Commit-
tee of the PATCH study to early terminate the study
when there is clear and substantial evidence of harm
[appendix III].
Discussion
In the PATCH study we aim to improve functional out-
come by limiting haematoma growth in ICH patients
who are on antiplatelet therapy. The Novoseven phase
IIb study, in which ICH patients were randomised to
receive recombinant factor VIIa (rFVIIa) or placebo,
supported the concept of outcome improvement by
hematoma growth reduction [14]. However, in the fol-
low-up phase III FAST trial, rFVIIa had no overall effect
on functional outcome despite limiting haematoma
growth [15]. A post-hoc subgroup analysis of the phase
III trial consisting of 160 patients aged ≤ 70 years, with
an ICH volume < 60 ml, an IVH volume < 5 ml and
onset to treatment time ≤ 2.5 hours did show a positive
effect of rFVIIa on neurological outcome after 3 months
[16]. We used the data from this analysis in designing
the eligibility criteria for the PATCH study.
Patients with intraventricular extension of the haema-
toma are excluded. Initially a maximum haematoma size
of 60 cc was an inclusion criterion. Many participating
centres had difficulty determining haematoma volume
and this held back inclusion of patients. Since the other
criteria lead to exclusion of patients with a poor prog-
nosis, we decided to withdraw the 60 cc limit. Further-
more, we decided not to include an upper age limit in
the inclusion criteria. Instead the patients must have
been completely independent before ICH. The 2.5 hour
onset-to-treatment time window is very narrow.
Although acute stroke patients do arrive in the emer-
gency rooms earlier after onset than before, a window of
2.5 hours would lead to exclusion of many patients.
Therefore, we decided to include patients as fast as pos-
sible with a maximum of six hours after onset. We
intend to perform a subgroup analysis of patients who
received the randomised treatment ≤ 2.5 hours after
onset.
When designing a study for a treatment that reduces
haematoma growth, patient selection is of utmost
importance. If a patient’s prognosis is already poor, irre-
spective of treatment - i.e. large infratentorial hematoma
or large ventricular extension, reducing haematoma
growth cannot improve outcome. Inclusion of such
patients will attenuate the possible treatment effect.
The relationship between APT use and outcome has
been the subject of considerable debate. A number of
studies described prospective cohorts of ICH patients to
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identify factors that can predict poor outcome in the
early stage of the disease. Large haematoma volume,
advanced age, decreased state of consciousness and a
poor neurological condition are often identified as
independent prognosticators. In several cohorts APT
use was identified as an independent predictor of poor
outcome [7-12]. In other studies the harmful effect of
antiplatelets was not established [17-19]. The most
recent report by Sansing et al. analysed the placebo
treated patients from the CHANT trial [19]. Seventy of
282 patients (25%) were using APT at the time of
onset of ICH. The APT patients were older, more likely
to be male, had hypertension more often and often had
a previous stroke. In this CHANT trial cohort, APT
use had no significant effect on haematoma growth or
neurological outcome. The authors concluded that
prior antiplatelet use does not affect haemorrhage
growth or outcome after ICH. However, there are sev-
eral issues which must be taken into account. The
CHANT trial allowed a maximum onset-to-treatment
time window of 6 hours [20]. In comparison in the
Novo Seven and FAST studies patients were included
within 4 hours. Also, the patients published by Sansing
had a mean ICH volume at baseline of 21.5 ml. The
mean volumes in Novo Seven and FAST were 24 and
23 ml. It has been established that even a small
increase in volume has a considerable impact on out-
come [6]. The CHANT patients were included later
and yet had a smaller haematoma volume. It could be
that the patients were a selected subgroup of ICH
patient who have a relatively good prognosis regardless
of the medication they used. The majority of the
patients included in the Sansing study used mono-ther-
apy whereas many patients nowadays receive combina-
tions such as aspirin and dipyridamole. A combination
APT regimen might have more effect on hematoma
growth and outcome after ICH.
Many colleagues have few doubts on the effectiveness
of platelet transfusion in ICH. They argue that a patient
with a life threatening haemorrhage who is on APT
should have platelet transfusion irrespective of the organ
in which the haemorrhage occurred. They feel a trial is
not justified since: “we don’t have not to prove that
water is wet”. Others are convinced that platelet transfu-
sion is a waste of money and energy of physicians.
Therefore we feel it is justified and important to per-
form a trial of platelet transfusion in ICH patients with
prior APT use.
Appendix I: participating centres with local
investigator (s) in alphabetical order
Alysis Ziekenhuis (J. Hofmeijer & S.E. Vermeer), Acade-
misch Medisch Centrum (Y.B. Roos), Atrium Medisch
Centrum (C.L. Franke), Canisius-Wilhelmina Ziekenhuis
(W.M. Mulleners), Catharina Ziekenhuis (K. Keizer),
Elkerliek Ziekenhuis (U.J. Dijkstra), Erasmus Medisch
Centrum (F. van Kooten), Flevo Ziekenhuis (I.M. Bron-
ner), Groene Hart Ziekenhuis (L.M.H. Kloos), Jeroen
Bosch Ziekenhuis (H.F. Viseé), HAGA Ziekenhuis (S.F.
T.M. de Bruijn), Kennemer Gasthuis (H.M.E. Bienfait),
Maasstad Ziekenhuis (R. Saxena), Martini Ziekenhuis
(J.F. Meilof), Meander Medisch Centrum (T.W.M. Raaij-
makers), Medisch Centrum Alkmaar (J.W.M. Brans),
Medisch Centrum Haaglanden (K. Jellema), Medisch
Centrum Leeuwarden (W.J. Schuiling), Onze Lieve
Vrouwe Gasthuis (P. Portegies), Orbis Medisch Centrum
(F.A. Rooyer), Reinier de Graaf Gasthuis (L.A.M. Aer-
den), Rode Kruis Ziekenhuis (W.D.M. van der Meulen),
Tergooiziekenhuizen (J.R. de Kruijk), TweeSteden Zie-
kenhuis (B.P.W. Jansen), Slotervaartziekenhuis (V.I.H.
Kwa), Spaarne Ziekenhuis (R.J. Meijer), St. Anna Zieken-
huis (A.E. Boon), St Antonius Ziekenhuis (W.J. Schone-
wille), St. Elisabeth Ziekenhuis (P.L.M. de Kort), St.
Franciscus Gasthuis (S.L.M. Bakker), St. Jansdal Zieken-
huis (D.J. Hofstee), St. Lucas Andreas Ziekenhuis (R.M.
van den Berg-Vos), UMC St. Radboud (E.J. van Dijk),
UMC Utrecht (C.J.M. Klijn), Vlietland Ziekenhuis (J.C.B.
Verhey), VU Medisch Centrum (M.C. Visser), Westfries
Gasthuis (T.C. van der Ree).
Appendix II: data safety monitoring board
- J.B. Reitsma - chairman, Department of Clinical Epide-
miology, Biostatistics and Bioinformatics, Academic
Medical Centre, Amsterdam, The Netherlands
- C.L. Franke, Department of Neurology, Atrium Med-
ical Centre Parkstad, Heerlen, The Netherlands
- P.W. Kamphuisen, Department of Vascular Medi-
cine, Academic Medical Centre, Amsterdam, The
Netherlands
Appendix III: steering committee members in
alphabetical order
L.A.M. Aerden (Reinier de Graaf Gasthuis), R.M. van
den Berg-Vos (St. Lucas Andreas Ziekenhuis), H.M.E.
Bienfait (Kennemer Gasthuis), K. de Gans (Academisch
Medisch Centrum), K. Jellema (Medisch Centrum Haa-
glanden), E.J. van Dijk (UMC St. Radboud), J.R. de
Kruijk (Tergooiziekenhuizen), C.J. Klijn (UMC Utrecht),
F van Kooten (Erasmus Medisch Centrum), P.L.M. de
Kort (St. Elisabeth Ziekenhuis), J.F. Meilof (Martini Zie-
kenhuis), T.W.M. Raaijmakers (Meander Medisch Cen-
trum), Y.B.W.E.M. Roos (Academisch Medisch
Centrum), R. Saxena (Maasstad Ziekenhuis), W.J. Scho-
newille (St Antonius Ziekenhuis), J.C.B. Verhey (Vliet-
land Ziekenhuis), S.M. Zinkstok (Academisch Medisch
Centrum).
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